洛铂对肝癌HepG2细胞增殖和调亡的作用及机制

李莹莹; 詹丽芬; 曾哲超; 许慎

doi:10.3969/j.issn.1001-5256.2018.04.018

洛铂对肝癌HepG2细胞增殖和调亡的作用及机制

DOI: 10.3969/j.issn.1001-5256.2018.04.018

福建医科大学附属漳州市医院肿瘤内科

详细信息

中图分类号: R735.7
计量
- 文章访问数: 2440
- HTML全文浏览量: 57
- PDF下载量: 413
- 被引次数: 0
出版历程
- 出版日期: 2018-04-20

Effect of lobaplatin on proliferation and apoptosis of hepatocellular carcinoma HepG2 cells and related mechanism of action

Department of Medical Oncology, Zhangzhou Hospital Affiliated to Fujian Medical University

摘要

摘要: 目的在体外细胞中研究洛铂对肝癌HepG2细胞在增殖、凋亡方面的作用及其机制。方法将HepG2细胞分为洛铂组（增殖实验:5、10、15μmol/L组;凋亡实验:10μmol/L;侵袭实验:4μg/ml）和对照组（不加药物）。利用CCK8法和流式细胞术分别检测2组HepG2细胞的增殖和凋亡情况。通过Western Blot初步检测2组细胞中增殖、凋亡相关蛋白NF-κB、Bcl-2、Bax、Bid、Puma、Caspase-3的表达变化。增殖实验采用双因素方差分析,凋亡实验采用χ2检验,侵袭实验采用t检验。结果在作用于细胞24、48、72 h后,对照组与实验组细胞生长增殖抑制率差异有统计学意义（F=273.5,P<0.01）,同一时间不同浓度间、同一浓度不同时间差异均有统计学意义（F分别为1857、1365,P值均<0.01）。2组间细胞凋亡率比较差异有统计学意义（χ2=1821,P<0.001）。实验组HepG2细胞中穿透Transwell小室的细胞数少于对照组（21.30±2.74 vs 45.00±4.26,t=11.89,P<0.001）。洛铂组HepG2细胞...
- 癌,肝细胞 /
- 洛铂 /
- 细胞增殖 /
- 细胞凋亡
Abstract: Objective To investigate the effect of lobaplatin on the proliferation and apoptosis of hepatocellular carcinoma (HCC) HepG2 cells in vitro and related mechanism of action.Methods HepG2 cells were divided into lobaplatin group (proliferation assay:5 μmol/L, 10 μmol/L, and 15 μmol/L; apoptosis assay:10 μmol/L; invasion assay:4 μg/ml) and control group (no drug was added) .CCK-8 assay and flow cytometry were used to measure the proliferation and apoptosis of HepG2 cells.Western Blot was used to measure the change in the expression of NF-κB, Bcl-2, Bax, Bid, Puma, and caspase-3 proteins involved in proliferation and apoptosis.A two-way analysis of variance was used for proliferation assay, the chi-square test was used for apoptosis assay, and the t-test was used for invasion assay.Results After intervention for 24, 48, and 72 hours, there was a significant difference in proliferation inhibition rate between the two groups (F = 273.5, P < 0.01) ; there was also a significant difference between different concentration groups at the same time point (F =1857, P < 0.01) , and all the concentration groups showed a significant change over time (F = 1365, P < 0.01) .As for apoptosis, there was a significant difference in apoptosis rate between the two groups (χ2= 1821, P < 0.001) .As for invasion ability, compared with the control group, the lobaplatin group had a significantly lower number of cells passing through the Transwell chamber (21.30 ± 2.74 vs 45.00± 4.26, t = 11.89, P < 0.001) .As for proteins, the lobaplatin group had a significant reduction in the expression of Bcl-2 and significant increases in the expression of NF-κB, Bax, Puma, and caspase-3.Conclusion Lobaplatin exerts a certain effect on the proliferation and apoptosis of HCC HepG2 cells by affecting the proteins involved in proliferation and apoptosis, but further studies are needed due to complex signaling pathways in cells.
- carcinoma, hepatocellular /
- lobaplatin /
- cell proliferation /
- apoptosis

HTML全文

参考文献(22)

[1]CHWN WQ, ZHENG RS, ZENG HM, et al.Cancer statistics in China[J].CA Cancer J Clin, 2016, 66 (2) :115-132.

[2]YE SL.Current challenges to primary liver cancer research[J].J Clin Hepatol, 2015, 31 (6) :819-823. (in Chinese) 叶胜龙.原发性肝癌研究当前面临的挑战[J].临床肝胆病杂志, 2015, 31 (6) :819-823.

[3]BRUIX J, SHERMAN M, American Association for the Study of Liver Diseases.Management of hepatocellular carcinoma:an update[J].Hepatology, 2011, 53 (3) :1020-1022.

[4]SCHWARTZ M, ROAYAIE S, LLOVET J.How should patients withhepatocellular carcinomarecurrence after liver transplantation betreated?[J].J Hepatol, 2005, 43 (4) :584-589.

[5]WHEATE NJ, WALKER S, CRAIG GE, et al.The status of platinum anticancer drugs in the clinic and in clinical trials[J].Dalton Trans, 2010, 39 (35) :8113-8127.

[6]WANG Y, ZHENG WL, MA WL.Lobaplatin inhibits the proliferation of hepatollular carcinoma through p53 apoptosis axis[J].Hepat Mon, 2012, 12 (10) :e6024.

[7]QIAN J, QIN SK, YANG AZ, et al.Experimental research about different inhibition of platinum complexes in human hepatocellular carcinoma cell line[J].Chin Clin Oncol, 2009, 14 (5) :414-417. (in Chinese) 钱军, 秦叔逵, 杨爱珍, 等.不同铂类药物对人肝癌细胞株抑制作用的实验研究[J].临床肿瘤学杂志, 2009, 14 (5) :414-417.

[8]Branch of Intervention, Chinese Medical Doctor Association.The expert consensus of Lobaplatin for Injection in the treatment of TACE for primary liver cancer (2016 Edition) [J/CD].Chin J Inter Rad:Electronic Edition, 2016, 4 (1) :1-3. (in Chinese) 中国医师协会介入医师分会.注射用洛铂在原发性肝癌TACE治疗中的专家共识 (2016版) [J/CD].中华介入放射学电子杂志, 2016, 4 (1) :1-3.

[9]LI Z, ZHU JY.An interpretation of diagnosis, management, and treatment of hepatocellular carcinoma (V2017) [J].J Clin Hepatol, 2017, 33 (9) :1655-1657. (in Chinese) 李照, 朱继业.《原发性肝癌诊疗规范 (2017年版) 》解读[J].临床肝胆病杂志, 2017, 33 (9) :1655-1657.

[10]JIAO ZY, YU ZY.Advances in surgical treatment of primary hepatocellular carcinoma[J/CD].Chin J Hepat Surg:Electronic Edition, 2016, 5 (5) :281-284. (in Chinese) 焦作义, 俞译元.原发性肝癌外科治疗进展[J/CD].中华肝脏外科手术学电子杂志, 2016, 5 (5) :281-284.

[11]PATT YZ, BARON AD, PARKS VA, et al.PhaseⅡtrial of gemcitabine (G) , oxaliplatin (O) , anderlotinib (T) for the treatment of hepatocellular carcinoma (HCC) and biliary treecancers (BTC) [J].J Clin Oncol, 2010, 28 (15 Suppl) :4153.

[12]QIN S, BAI Y, LIM HY, et al.Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia[J].J Clin Oncol, 2013, 31 (28) :3501-3508.

[13] National Healthand Family Planning Commossion of the People’s Republic of China.Diagnosis, management, and treatment of hepatocellular carcinoma (V2017) [J].J Clin Hepatol, 2017, 33 (8) :1419-1431. (in Chinese) 中华人民共和国国家卫生和计划生育委员会.原发性肝癌诊疗规范 (2017年版) [J].临床肝胆病杂志, 2017, 33 (8) :1419-1431.

[14]WANG N, LV YZ, XU AH, et al.Application of lobaplatin in trans-catheter arterial chemoembolization for primary hepatic carcinoma[J].Asian Pac J Cancer Prev, 2014, 15 (2) :647-650.

[15]WU Q, QIN SK, TENG FM, et al.Lobaplatin arrests cellcycle progression in human hepatocellular carcinoma cells[J].J Hematol Oncol, 2010, 3:43.

[16]LIU WB, YANG YT, LI FC.Research of effects of lobaplatin on transcatheter arterial chemoembolization of Primary Hepatic Carcinoma[J].Shenzhen J Integr Tradit Chin West Med, 2015, 25 (5) :12-13. (in Chinese) 刘伟波, 杨有甜, 李凤彩.洛铂介入治疗原发性肝癌的临床研究[J].深圳中西医结合杂志, 2015, 25 (5) :12-13.

[17]ZHAO C, WANG XJ, WANG S, et al.Lobaplatin combined floxuridine/pirarubicin-based transcatheter hepatic arterial chemoembolization for unresectable primary hepatocellular carcinoma[J].Asian Pac J Cancer Prev, 2014, 15 (5) :2057-2060.

[18]ASHKENAZI A, FAIRBROTHER WJ, LEVERSON JD, et al.From basic apoptosis discoveries to advanced selective BCL-2family inhibitors[J].Nat Rev Drug Discov, 2017, 16 (4) :273.

[19]AMIRI KI, RICHMOND A.Role of nuclear fact or-kappa B in melanoma[J].Cancer Met astasis Rev, 2005, 24 (2) :301-313.

[20]LALIER L, CARTRON PF, JUIN P, et al.Bax activation and mitochondrial insertion during apoptosis[J].Apoptosis, 2007, 12 (5) :887-896.

[21]SONG H, WEI M, LIU W, et al.Cisplatin induced apoptosis of ovarian cancer A2780s cells by activation of ERK/p53/PUMA signals[J].Histol Histopathol, 2018, 33 (1) :73-79.

[22]PU X, STORR SJ, ZHANG Y, et al.Caspase-3 and caspase-8 expression in breast cancer:caspase-3 is associated with survival[J].Apoptosis, 2017, 22 (3) :357-368.

施引文献

资源附件(0)

访问统计